Dr. Muir’s clinical interests include hepatitis C, primary sclerosing cholangitis, cirrhosis, liver transplantation, clinical trials, healthcare disparities in liver disease and outcome research. He has working relationships with several medical companies, including AbbVie, Gilead Sciences, Janssen Pharmaceuticals, Inovio, Cook Medical and others.
Dr. Muir earned his medical degree from Duke University School of Medicine, where he also completed his residency and fellowship.
More articles on GI & endoscopy:
5 most read GI/endoscopy stories: May 23 – May 27
FDA grants accelerated approval to primary biliary cholangitis treatment drug: 4 notes
EndoStim presents positive results on 4 GERD, patient studies — 4 takeaways
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.